

About GeoVax Labs, Inc

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against a wide range of infectious diseases and cancers using a novel, proprietary platform GV-MVA-VLP™.

September 25, 2020

Up-listed to Nasdaq and closed \$12.8M Public Offering

February 11, 2021

Closing of \$10.3M Follow-on Offering

GeoVax Labs, Inc. Nasdaq: GOVX	
Recent Stock Price (06/30/21)	\$5.00
Market Capitalization	\$31.6M
Shares Outstanding	6.3M
Fiscal Year End	Dec 31

Investment Highlights



Proprietary Vaccine Platform — produces noninfectious Virus-Like-Particles (VLPs) in a vaccinated individual with an extensive, clinically-proven safety profile, highly durable immune response; potential for single-dose, highly-effective vaccines, requiring minimal refrigeration storage.


COVID-19 Four vaccine candidates under development including a single-dose "universal" coronavirus vaccine and a vaccine for high-risk populations; proceeding through animal challenge testing; and preparation for human clinical testing. Data milestones expected H2 '21.

Immuno-oncology Program showing promising results; potential for multiple cancer indications; focused on advancing to clinical trials.

HIV Vaccine completed through Phase 2a; three clinical programs planned or in progress:

- · Prevention (HVTN/NIH)
- Functional Cure (UCSF)

Single-dose 100% protection demonstrated with Ebola, Lassa, Marburg, and Sudan fever vaccines in IND-enabling studies; non-dilutive funding for completion of animal testing (non-human primates). Data milestones expected H2 '21.






COVID-19 Vaccine Program

Four vaccines GEO-CM01-04 designed; animal testing results: H2 '21.

Universal Coronavirus vaccine Focused on providing immunity to SARS-CoV-2 and seasonal coronavirus strains.

"Single-dose, universal coronavirus vaccine" for COVID-19, COVID-20, etc.



Advancing to Clinic Focused on accelerating development into clinical testing.

No FDA requirement for toxicology testing expected.


Scale up for Emergency Use Authorization readiness during Phase 1a/1b clinical trial.

Immuno-oncology Program

Triple-threat Approach

- Tumor antigen specific immune responses stimulated
- 2 Immune inhibition blocked with checkpoint inhibitors
- 3 Tumor cells killed using an oncolytic virus

GeoVax Concept for Cancer Immunotherapy



Tumor Regression

Stimulate MVA-VLP with tumor antigen to provoke immune system

Block Checkpoint inhibitor to reverse immune tolerance

Kill Achieve oncolysis using armed vaccinia virus

GeoVax - A Compelling Investment Opportunity

- Focused on areas of critical medical needs providing significant commercial opportunities;
- Clinical stage and IND-enabling programs successfully advancing;
- Novel, differentiated platform validated across infectious disease vaccines and immuno-oncology;
- New Filings Expands and Strengthens Intellectual Property Portfolio;
- Capital structure and balance sheet supporting advancing programs into milestone clinical development

Strong IP Protection



IR Contact: Tristan Traywick CORE IR / 377 Oak Street Garden City, NY 11530 investor@geovax.com

